Entera Bio (ENTX) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
6 Nov, 2026Executive summary
Q3 net loss was $15.6M, including $8.3M of net financial expense; operating loss was $7.3M, versus a $3.2M net loss in Q3 2025.
July’s private placement generated $260.9M net proceeds; cash resources were projected to fund planned operations into 2030.
EB613 advanced toward a Phase 3 registrational study, with first site activation planned for late 2026 and topline results anticipated in H2 2028.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Entera Bio
- EB613 advances toward Phase III with FDA-aligned BMD endpoints and funding runway into 2030.ENTX
3rd Annual Guggenheim Healthcare Innovation Conference - Eight shareholder votes would expand equity capacity and reset compensation after a $275 million financing.ENTXProxy filing
- Eight proposals, including equity plan and compensation changes, recommended for approval.ENTXProxy filing
- Registers 134.8M shares for resale after $275M private placement to fund pivotal oral peptide trials.ENTXRegistration filing
- Oral anabolic EB613 targets the osteoporosis treatment gap with a pivotal phase III trial ahead.ENTXCanaccord Genuity's 46th Annual Growth Conference
- $275M financing and FDA-aligned Phase 3 for EB613 secure pipeline and cash runway to 2030.ENTXQ2 2026
- Key votes include director elections, compensation, equity plan, and auditor approval.ENTXProxy filing
- Proxy covers director elections, compensation, equity plan, capital structure, and auditor approval.ENTXProxy filing
- Annual meeting covers director elections, compensation, equity plan, and capital increase proposals.ENTXProxy filing